JP2002534083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002534083A5 JP2002534083A5 JP2000592399A JP2000592399A JP2002534083A5 JP 2002534083 A5 JP2002534083 A5 JP 2002534083A5 JP 2000592399 A JP2000592399 A JP 2000592399A JP 2000592399 A JP2000592399 A JP 2000592399A JP 2002534083 A5 JP2002534083 A5 JP 2002534083A5
- Authority
- JP
- Japan
- Prior art keywords
- mammal
- host mammal
- host
- cells
- donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000124008 Mammalia Species 0.000 description 73
- 210000004698 lymphocyte Anatomy 0.000 description 30
- 239000000427 antigen Substances 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 11
- 230000001400 myeloablative effect Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003018 immunosuppressive agent Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 229940125721 immunosuppressive agent Drugs 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- PBUUPFTVAPUWDE-UGZDLDLSSA-N 2-[[(2S,4S)-2-[bis(2-chloroethyl)amino]-2-oxo-1,3,2lambda5-oxazaphosphinan-4-yl]sulfanyl]ethanesulfonic acid Chemical group OS(=O)(=O)CCS[C@H]1CCO[P@](=O)(N(CCCl)CCCl)N1 PBUUPFTVAPUWDE-UGZDLDLSSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229950000547 mafosfamide Drugs 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/222,011 US6428782B1 (en) | 1997-05-23 | 1998-12-31 | Non-myeloablative tolerogenic treatment |
| US09/222,011 | 1998-12-31 | ||
| PCT/US1999/030704 WO2000040701A2 (en) | 1998-12-31 | 1999-12-23 | Non-myeloablative tolerogenic treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002534083A JP2002534083A (ja) | 2002-10-15 |
| JP2002534083A5 true JP2002534083A5 (enExample) | 2007-02-22 |
Family
ID=22830367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000592399A Pending JP2002534083A (ja) | 1998-12-31 | 1999-12-23 | 骨髄機能廃絶性ではない寛容原性の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6428782B1 (enExample) |
| EP (3) | EP1141246A2 (enExample) |
| JP (1) | JP2002534083A (enExample) |
| CA (1) | CA2356434A1 (enExample) |
| IL (1) | IL143485A0 (enExample) |
| WO (1) | WO2000040701A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140796A0 (en) * | 2001-01-08 | 2002-02-10 | Hadasit Med Res Service | An autologous anti-cancer vaccine |
| JP3734461B2 (ja) | 2001-08-08 | 2006-01-11 | 松下電器産業株式会社 | ライセンス情報変換装置 |
| US20040151700A1 (en) * | 2001-10-30 | 2004-08-05 | Harlan David M. | Ex-vivo rescue of transplantable hematopoietic stem cells following myeloablative injury |
| AU2002952834A0 (en) * | 2002-09-16 | 2002-12-05 | The Walter And Eliza Hall Institute Of Medical Research | A method of treating an autoimmune disease |
| US20050112122A1 (en) * | 2003-09-02 | 2005-05-26 | Greiner Dale L. | Generation of hematopoietic chimerism and induction of central tolerance |
| ZA200801696B (en) * | 2005-07-22 | 2009-08-26 | Univ California | Heparin compositions and selection inhibition |
| ATE552837T1 (de) * | 2005-12-02 | 2012-04-15 | Univ Johns Hopkins | Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen |
| WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
| WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
| WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
| US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
| WO2009067690A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for safe and effective treatment using oxazaphosphorine drugs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273738A (en) | 1990-03-03 | 1993-12-28 | Fred Hutchinson Cancer Research Center | Radiation delivery to lymphoid and marrow tissues |
| CA2126094A1 (en) | 1992-01-08 | 1993-07-22 | David H. Sachs | Induced tolerence to xenografts |
| US5876708A (en) | 1992-02-19 | 1999-03-02 | The General Hospital Corporation | Allogeneic and xenogeneic transplantation |
| US5589582A (en) | 1992-10-27 | 1996-12-31 | Biotransplant, Inc. | Polynucleotides en coding porcine cytokines |
| AU7404494A (en) | 1993-07-21 | 1995-02-20 | Cellpro, Incorporated | Methods and compositions for preventing immune rejection of solid organ grafts |
| EP0721346B1 (en) * | 1993-09-02 | 1998-06-10 | Trustees of Dartmouth College | Methods for inducing antigen-specific t cell tolerance |
| US5635156A (en) | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US5514364A (en) | 1993-09-13 | 1996-05-07 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| IL112969A (en) * | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| WO1996031229A1 (en) * | 1995-04-05 | 1996-10-10 | Beth Israel Hospital Association | Inhibiting rejection of a graft |
| WO1996037208A1 (en) | 1995-05-25 | 1996-11-28 | Baxter International Inc. | Allogeneic cell therapy for cancer following allogeneic stem cell transplantation |
| EP1011694A4 (en) * | 1996-11-15 | 2000-11-15 | Baxter Int | TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION |
| IL132845A0 (en) * | 1997-05-23 | 2001-03-19 | Hadasit Med Res Service | Non-myeloablative tolerogenic treatment |
-
1998
- 1998-12-31 US US09/222,011 patent/US6428782B1/en not_active Expired - Lifetime
-
1999
- 1999-12-23 EP EP99968946A patent/EP1141246A2/en not_active Withdrawn
- 1999-12-23 EP EP04024995A patent/EP1498136A2/en not_active Withdrawn
- 1999-12-23 JP JP2000592399A patent/JP2002534083A/ja active Pending
- 1999-12-23 IL IL14348599A patent/IL143485A0/xx not_active IP Right Cessation
- 1999-12-23 CA CA002356434A patent/CA2356434A1/en not_active Abandoned
- 1999-12-23 EP EP04024994A patent/EP1498479A2/en not_active Withdrawn
- 1999-12-23 WO PCT/US1999/030704 patent/WO2000040701A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Satoh et al. | Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. | |
| Norton | Evolving concepts in the systemic drug therapy of breast cancer | |
| Yoshizawa et al. | Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy | |
| Salup et al. | Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy. | |
| JP2002534083A5 (enExample) | ||
| JP2004506598A5 (enExample) | ||
| AU633940B2 (en) | Method for stimulating proliferation of peripheral blood lymphocytes | |
| JP2002506831A5 (enExample) | ||
| Fujii et al. | Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients | |
| Cany et al. | Umbilical cord blood–derived cellular products for cancer immunotherapy | |
| CN115137752A (zh) | 用于干细胞移植的方法 | |
| Fagan et al. | Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells | |
| Locatelli et al. | Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia | |
| Wecker et al. | CD4+ T cells, without CD8+ or B lymphocytes, can reject xenogeneic skin grafts | |
| Crowley et al. | Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells | |
| Gordon | Circulating inhibitors of granulopoiesis in patients with aplastic anaemia | |
| EP0460065B1 (en) | A process for the generation of proliferating cd4 lymphocytes | |
| Marin et al. | “Off the Shelf” CAR‐T/NK Cells | |
| Gold et al. | Autolymphocyte therapy: II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells | |
| Gold et al. | Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma | |
| Gold et al. | Autolymphocyte Therapy: III. Effective Adjuvant Adoptive Cellular Therapy with in Vivo Anti-tumor Specificity against Murine Melanoma and Carcinoma Using ex-Vivo-Activated Memory T-Lymphocytes | |
| Chester et al. | Treatment of an established graft-versus-host reaction in AKR mice by adoptive immunotherapy | |
| Mitsuma et al. | Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells | |
| Rosenberg et al. | The use of lymphoid cells expanded in IL-2 for the adoptive immunotherapy of murine and human tumors | |
| DING et al. | Opportunities and challenges of NK cell therapy. |